Skip to main content

Table 1 CD20-CD3 bispecific T cell engager for relapsed or refractory diffuse large B cell lymphoma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Agent

Odronextamab

Mosunetuzumab

Epcoritamab

Glofitamab

Targets

CD20, CD3

CD20, CD3

CD20, CD3

CD20, CD3

IG

Human IgG4

Human IgG1

Human IgG1

Human IgG

Administration

i.v

s.c

i.v

i.v

Patients (n)

35

22

18

28

Median prior therapy

3 (1–11)

4 (1–8)

NA

3 (1–12)

Prior CAR T

69%

22%

NA

NA

ORR

44%

60%

67%

50%

CR

38%

20%

33%

29%

PFS

NR

NR

NR

NR

OS

NR

NR

NR

NR

CRS, any grade

63%

21%

58%

57.9%

  ≥ 3

5%

0

0

3.8%

NT, any grade

0

22%

9%

0

  ≥ 3

0

0

3%

0

Reference

[24]

[25]

[26]

[27]

 

ASH,2020, #400

ASH,2020, #401

ASH,2020, #403

ASH,2020, #404